Market News AIOpen the app

VBIO stock news · Valion Bio, Inc.

Stories about Valion Bio, Inc. (VBIO) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for VBIO

Follow Valion Bio, Inc. (VBIO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VBIO
Free on the App Store and Google Play, or on the web.
  1. Oct 22, 2026, 8:03 AM ET · New boss

    Valion Bio, Inc. shares news about Dean Zikria becoming the temporary CEO.

    Neutral

    Valion Bio filed a report about its new interim chief executive's first 30-day assessment. The report gives no findings, so it does not change the company's outlook.

  2. Oct 15, 2026, 8:27 AM ET · Market

    12 health care stocks are changing a lot before the market opens on Thursday.

    Neutral

    Valion Bio shares rose in pre-market trading. The roundup gives no company update explaining the move, so it does not change the business outlook.

  3. Oct 15, 2026, 8:17 AM ET · Market

    Valion Bio, Inc. shares news about finishing a study on LarmorBio's BioScan-NMR™ system.

    Neutral

    Valion Bio said it finished an initial evaluation of LarmorBio's BioScan-NMR platform, but reported no findings. The filing does not show a change in Valion Bio's outlook.

  4. Oct 14, 2026, 8:21 AM ET · Market

    Valion Bio, Inc. shares news about its subsidiary, Velocity Bioworks, Inc.

    Neutral

    Valion Bio filed a report saying it issued a press release about its subsidiary, but the release's details are missing. This filing alone does not change the company's outlook.

  5. Oct 8, 2026, 6:17 AM ET · Deal

    Valion Bio, Inc. has made a big deal with 3i, LP to buy and sell shares worth up to $8.4 million.

    Neutral

    Valion Bio agreed to sell preferred shares and warrants for $50,000, subject to closing conditions. The cash and possible increase in shares leave its outlook unchanged.

  6. Oct 6, 2026, 7:48 AM ET · Market

    Valion Bio, Inc. says Thomas Jensen is the new chair of its board.

    Neutral

    Valion Bio's filing points to a press release about new board chair Thomas Jensen's expertise and goals. It gives no specific business change, so it does not change the company's outlook.

  7. Aug 17, 2026, 6:17 AM ET · Market

    Valion Bio, Inc. discloses unregistered equity securities transactions (VBIO).

    Good for VBIO

    Valion Bio, Inc. has disclosed unregistered sales of equity securities in a recent SEC filing, which raises concerns about potential dilution for existing shareholders. This news is likely to negatively affect the stock's performance as investors react to the implications of these sales.